

AD _____

Award Number: DAMD17-96-C-6105

TITLE: Treatment of Metastatic Breast Carcinoma Refractory to
Doxorubicin with Liposomal-Annamycin

PRINCIPAL INVESTIGATOR: Aysegul A. Sahin, M.D.

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer
Center
Houston, Texas 77030

REPORT DATE: October 2001

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030317 008

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 2001	3. REPORT TYPE AND DATES COVERED Final (23 Sep 96 - 30 Sep 01)	
4. TITLE AND SUBTITLE Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin with Liposomal-Annamycin			5. FUNDING NUMBERS DAMD17-96-C-6105	
6. AUTHOR(S) Aysegul A. Sahin, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Texas M.D. Anderson Cancer Center Houston, Texas 77030 E-Mail: Asahin@mail.mdanderson.org / rperezso@montefiore.org			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) We studied the toxicity and antitumor activity of Liposomal-Annamycin in patients with metastatic breast carcinoma. Sixteen patients were treated. Toxicity was mild and consisted mostly of bone marrow suppression, particularly granulocytopenia. Non-hematological toxicity was less than what is usually seen with other anthracyclines. No responses were seen.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 6	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Report	4
Objective of the Study.....	4
Eligibility Criteria	4
Patient Characteristics.....	5
Toxicity.....	6
Antitumor Activity	6
Correlative Tissue Studies.....	6
Conclusions.....	6
References.....	6

INTRODUCTION

Liposomal-Annamycin is a liposome entrapped new anthracycline antibiotic, which has shown lack of cross-resistance in vitro and in vivo in different cell lines that express P-glycoprotein and MRP. In a Phase I study conducted in patients with solid tumors, the dose limiting toxicity was myelosuppression. No alopecia, muositis, cardiac, skin, nor gastrointestinal toxicities were observed. The maximum tolerated dose was 210 mg/m² administered intravenously every 3 weeks. Because the multidrug resistance phenotype has been associated with some human malignancies, particularly acute leukemia and breast carcinoma, when they become refractory to standard chemotherapy, we performed a Phase II clinical study of liposomal-Annamycin in patients with metastatic breast carcinoma refractory to doxorubicin. This report summarizes the results of this study.

REPORT

The study accrued a total of 16 patients. No clinical responses were observed. We conclude that Liposomal-Annamycin is an inactive agent in this heavily pretreated patient population.

OBJECTIVE OF THE STUDY

1. To evaluate the antitumor activity of Liposomal-Annamycin in patients with metastatic breast carcinoma resistant to anthracyclines.
2. To correlate responses with MDR-1 expression in tumor tissue.

ELIGIBILITY CRITERIA

1. Metastatic breast carcinoma
2. Anthracycline-resistant. Amended during the last year to allow accrual of patients who have received prior anthracyclines in the adjuvant setting, but in whom there is no demonstration of clinical resistance to anthracyclines. This modification was introduced to test Liposomal-Annamycin in a less heavily pretreated population since no responses were seen in the first 14 patients.
3. Measurable disease
4. Life expectancy >12 weeks
5. Prior anthracycline <350 mg/m² of doxorubicin equivalent by bolus, <450 mg/m² by prolonged infusion
6. Adequate bone marrow function
7. Ejection fraction >55%

PATIENT CHARACTERISTICS

A total of sixteen patients were entered in the study. The recommended dose was 190mg/m². It was escalated to 210 mg/m² in 8 courses and to 250 mg/m² in 2 courses. The following Table summarized the characteristics of the patients entered.

Number of patients entered	16
Number of patients evaluable	16
Age median (range)	47 (34-73)
Performance status	
1	14
2	2
Sex: female	16
Race:	
Black	7
Hispanic	4
White	5
Histology	
Ductal carcinoma, invasive	16
Prior therapy	
Chemotherapy	16
Hormonal therapy	3
Radiation therapy	6
Surgical therapy	7
Prior chemotherapy: number of regimens	
1	4
2	2
3	8
4	2
Number of agents	
≤3	3
>3	13

TOXICITY

Liposomal-Annamycin is well tolerated, the dose limiting toxicity being myelosuppression particularly granulocytopenia. The nadir occurs on days 11-14 and in no cases the second dose was delayed. No significant thrombocytopenia was seen. Mild gastrointestinal toxicity such as nausea and vomiting was observed in about 30% of patients and mild mucositis was rare. No alopecia was observed. Fatigue was observed in only a few patients. No events of potential cardiotoxicity were recorded. These results lead to the conclusion that Liposomal-Annamycin is less toxic than the other anthracyclines doxorubicin (Adriamycin) and Daunorubicin.

ANTITUMOR ACTIVITY

No partial responses have been observed in this group of 16 patients. However, only four of these patients received Liposomal-Annamycin as a second line therapy. It is well known that pan-resistance to most agents occurs after 2 and 3 different regimens are given to patients with metastatic solid tumors. As a result, we tried to accrue patients with one prior regimen as adjuvant therapy or for metastatic disease. Unfortunately, this has resulted in a lower accrual because these patients have a number of alternative options. However, we do not believe patients with >2 prior regimen should be entered in the future since we have already demonstrated that there were no responses in 16 such patients.

CORRELATIVE TISSUE STUDIES

Five tissue specimens were obtained pre-therapy for MDR analysis. These samples are kept frozen in Dr. Sahin's laboratory. However, since no responses were observed, the proposed correlation studies can not be performed.

CONCLUSIONS

Results obtained suggest that Liposomal-Annamycin is very well tolerated with grade 3 granulocytopenia being observed in a minority of patients. Non-hematological toxicity is minimal.

No tumor responses have been observed. However, the grand majority of patients had received two or more prior chemo regimens.

REFERENCES

1. Booser D, Esparza-Guerra L, Zou Y, Priebe W, Perez-Soler R. Liposomal-annamycin. Phase I clinical and pharmacological study. Proceed. ASCO 16:762 p217a, 1997.
2. Booser D, Perez-Soler R, Cossum P, Esparaza-Guerra L, Wu Q-P, Zou Y, Priebe W, Hortobagyi G. Phase I study of liposomal annamycin. Cancer Chemother Pharmacol 46:427-432, 2000.